Why the Mesoblast (ASX:MSB) share price is sinking 11% lower

The Mesoblast limited (ASX:MSB) share price is sinking lower on Tuesday. Here's what you need to know…

The Mesoblast limited (ASX: MSB) share price has come under pressure on Tuesday after the release of an announcement.

At the time of writing the allogeneic cellular medicines developer's shares are down 11% to $4.03.

What did Mesoblast announce?

This morning Mesoblast announced the top-line results from the landmark DREAM-HF Phase 3 randomised controlled trial of its allogeneic cell therapy rexlemestrocel-L (REVASCOR) in 537 patients with advanced chronic heart failure.

According to the release, after a 30-month follow-up, patients with advanced chronic heart failure who received a single endomyocardial treatment with rexlemestrocel-L on top of maximal therapies had a 60% reduction in the incidence of heart attacks or strokes and a 60% reduction in death from cardiac causes when treated at an earlier stage in the progressive disease process.

However, despite this reduction in the pre-specified endpoint of cardiac death, there was no reduction in the recurrent non-fatal decompensated heart failure events. This was the trial's primary endpoint.

Management believes this suggests that rexlemestrocel-L reduces mortality by mechanisms that are distinct from those of existing drugs that reduce hospitalisation rates but do not significantly impact cardiac mortality.

Mesoblast's Chief Executive, Dr Silviu Itescu, commented: "There is an urgent need for new therapies that can reduce the high death rates in heart failure patients by different modes of action from existing drugs which reduce hospitalization rates but have not significantly reduced mortality rates."

"The reduction in mortality seen with rexlemestrocel-L in advanced chronic heart failure underlines the power of this technology and the commitment of Mesoblast to address diseases in patients with high unmet need which are refractory to existing therapies," he added.

What now?

While the primary endpoint may not have been achieved, management still sees potential for the therapy.

Mesoblast's Chief Medical Officer, Dr Fred Grossman, explained: "We expect the mortality benefit observed in this seminal Phase 3 trial will support a potential path for approval of rexlemestrocel-L in patients with advanced chronic heart failure. We are planning to meet and discuss potential pathways to approval based on mortality reduction with the United States Food and Drug Administration."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Thumbs down Facebook icon over dark screen.
Broker Notes

Why these 5 ASX shares were downgraded by brokers this week

Market analysts explain why they've downgraded these ASX stocks.

Read more »

Worried unemployed woman sits on white chair waiting for job interview
ASX Share Market News

ASX 200 volatile as unemployment rises to a 5-year high, dampening rate hike fears

The unemployment rate rose to 4.9% in October, the highest level since October 2021.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Domino's Pizza, Super Retail, PLS shares

Let's check out some new ratings on ASX shares today.

Read more »

Smiling woman taking a video through a plane window with her phone.
Broker Notes

Qantas or Virgin shares. Which ASX airline has more upside?

Will either share take off soon?

Read more »

Sad man sitting at desk and grabbing his head as he looks at a laptop.
ASX Share Market News

5 things to watch on the ASX 200 on Thursday

Investors might want to load their PlayStations and avoid another potential red day on the market today.

Read more »

A young well-dressed couple at a luxury resort celebrate successful life choices.
Opinions

My 3 biggest ASX portfolio winners and the one I'm buying more of

These businesses have significant growth potential.

Read more »

A man rests his chin in his hands, pondering what is the answer?
ASX Share Market News

Think you know the ASX? Try guessing the top 20 ASX shares of the past 20 years

Alongside the familiar names sit a couple of surprising names whose massive gains were supercharged by where they started two…

Read more »

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »